Phase 2 N=32 Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Melanoma · Skin Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 18.8 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Primary: Progression-Free Survival (PFS) — 8.0; 8.1; 7.1 months — p=0.3037
Phase 2 N=160 Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Islet Cell Carcinoma · Neuroendocrine Carcinoma · Neuroendocrine Tumor
Primary: Objective Response Rate: Percentage of Participants With Best Over All Response of Complete Response or Partial Response by Central Radiology Review (Stratum 1) Based on…
Phase 2 N=78 Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation
Pediculus Humanus Capitis (Head Lice)
Primary: Percentage of Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control) — 56; 50…
Phase 2 N=203 Phase 2 Study of Indomethacin Capsules to Treat Dental Pain
Dental Pain
Primary: Total Patient Pain Relief Over 0 to 8 Hours. — 10.794; 12.564; 14.822; 3.019 units on a scale — p=<0.001
Phase 2 N=30 Comparative Evaluation of Corneal Staining With Balafilcon A Lenses and Two Multi-Purpose Solutions
Myopia · Hyperopia · Astigmatism
Primary: Number of Eyes With No Change in Corneal Staining — 16; 17; 19; 14 eyes
Phase 2 N=30 A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
Uterine Cancer
Primary: 3-year Overall Survival — 17 partipants
Phase 2 N=202 Study of Diclofenac Capsules to Treat Dental Pain
Dental Pain
Primary: Total Patient Pain Relief Over 0 to 12 Hours. — 17.770; 16.893; 14.685; 5.486 units on a scale — p=<0.001
Phase 2 N=351 ELND005 in Patients With Mild to Moderate Alzheimer's Disease
Alzheimer Disease
Primary: Change From Baseline to Week 78 in Neuropsychological Test Battery (NTB) Z-score (Full Analysis Set; FAS) — -0.383; -0.350 Scores on a Scale — p=0.71
Phase 2 N=18 Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans
Dermatofibrosarcoma Protuberans
Primary: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and…
Phase 2 N=30 Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer
Prostatic Neoplasms
Primary: Percentage of Participants With a Good Toxicity Outcome Who Experienced an Acute Rectal Toxicity and Received Topical Administrations of Amifostine in Conjunction With…
Phase 2 N=254 Study of Naproxen Capsules to Treat Dental Pain
Dental Pain
Primary: Analysis of Total Pain Relief (TOTPAR) Over 0 to 12 Hours (TOTPAR-12) After Time 0 — 25.868; 31.948; 24.373; 28.549 units on a scale — p=<0.001
Phase 2 N=14 Aripiprazole Augmentation of Antidepressants in PTSD
PTSD
Primary: Clinician Administered PTSD Scale (CAPS) — 18.6; 9.58 Units on a scale
Phase 2 N=155 An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
Pancreatic Cancer
Primary: Overall Survival (OS) — 6.5; 6.9 Months
Phase 2 N=70 CTS-1027 in Interferon-Naive Hepatitis C Patients
Hepatitis C
Primary: Mean Change in HCV-RNA (Hepatitis C Virus Ribonucleic Acid) Levels From Baseline Through 24 Weeks of Treatment — -0.48; -0.12 log (IU/mL)